TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8218536

Group type: EXPERIMENTAL
Intervention: Initial induction consolidation chemotherapy for newly diagnosed AML
Number of subjects: 199
Study: 2438841

Group type: EXPERIMENTAL
Intervention: Blue-green argon laser treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Red krypton laser treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 71
Study: 29996886

Group type: EXPERIMENTAL
Intervention: CCM intervention using the Flinders Program of chronic condition management (CCM)
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: Standardised yet flexible motivational process combined with evidence-based interventions
Number of subjects: 300000
Study: 26898600

Group type: EXPERIMENTAL
Intervention: Self-management educational group program
Number of subjects: 475
Study: 24199655

Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 536

Group type: COMPARATOR
Intervention: No gastric lavage (Control)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 536
Study: 22592966

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 336
Study: 21432590

Group type: EXPERIMENTAL
Intervention: High intensity physical activity (PA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Methylphenidate (MTP)
Number of subjects: 25
Study: 19720587

Group type: EXPERIMENTAL
Intervention: BMD screening readiness measured by a three-item summative index
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Improving knowledge about osteoporosis and BMD testing
Number of subjects: 636
Study: 16054267

Group type: EXPERIMENTAL
Intervention: Young adults (16 participants)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Elderly adults (16 participants)
Number of subjects: 32
Study: 14511962

Group type: EXPERIMENTAL
Intervention: Oral plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol only
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Number of subjects: 2219

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2219
Study: 10389710

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 gel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Negative fetal fibronectin test with 0.5 mg PGE2 gel
Number of subjects: 61
Study: 8896855

Group type: EXPERIMENTAL
Intervention: 30 g EMLA cream
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 83
Study: 1670586

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) plus zidovudine (ZDV), daily doses of IL-2 from 1.5 to 12 x 10(6) IU/m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) plus zidovudine (ZDV), higher doses of IL-2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) plus zidovudine (ZDV)
Number of subjects: 9
Study: 4072925

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 to 50 mg/day)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 30306399

Group type: EXPERIMENTAL
Intervention: Ritualistic intervention
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Repetitive behavior
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cognitive load
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Undirected movement
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of undirected movement and cognitive load
Number of subjects: 180
Study: 27231927

Group type: EXPERIMENTAL
Intervention: Dietitian-delivered nutrition counseling intervention (10 hours over 6 months)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 354
Study: 24807391

Group type: EXPERIMENTAL
Intervention: Preadmission statin use
Number of subjects: 295

Group type: COMPARATOR
Intervention: Statin-naive group
Number of subjects: 295
Study: 20188847

Group type: EXPERIMENTAL
Intervention: Systemic theophylline (nonselective adenosine receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled lidocaine (local anesthetic)
Number of subjects: 0
Study: 17674020

Group type: EXPERIMENTAL
Intervention: PDT combined with intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: PDT
Number of subjects: 61
Study: 17954055

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 1053
Study: 15502060

Group type: COMPARATOR
Intervention: Patient-controlled IV opioid analgesia (PCIA) with fentanyl
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with 0.08% bupivacaine and fentanyl 1.6 microg/mL
Number of subjects: 242
Study: 10904462

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 9314296

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (arm A)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Cisplatin/paclitaxel (arm B)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 353

Group type: COMPARATOR
Intervention: Cisplatin/paclitaxel (GOG III)
Number of subjects: 353
Study: 8349066

Group type: EXPERIMENTAL
Intervention: Oral omeprazole, 40 mg per day (n = 31)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Injection therapy (adrenaline 1:10,000 plus polidocanol 1% injection associated with oral ranitidine 300 mg per day) (n = 21)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 3538488

Group type: EXPERIMENTAL
Intervention: 67% oxygen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Air
Number of subjects: 19

Group type: COMPARATOR
Intervention: Air delivered from a cylinder
Number of subjects: 19
Study: 31401045

Group type: EXPERIMENTAL
Intervention: Educational pamphlet and slideshow
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CPAP use (in both groups)
Number of subjects: 48
Study: 28419997

Group type: EXPERIMENTAL
Intervention: Genetically predicted circulating leptin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted soluble plasma leptin receptor (sOB-R) levels
Number of subjects: 0
Study: 26332539

Group type: EXPERIMENTAL
Intervention: USL261 (2.5, 5.0, and 7.5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: MDZ-inj IN (5.0 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: MDZ-inj IV (2.5 mg)
Number of subjects: 25
Study: 24172626

Group type: EXPERIMENTAL
Intervention: Chloramphenicol eye drops
Number of subjects: 33

Group type: COMPARATOR
Intervention: Systemic peroral antibiotics
Number of subjects: 33
Study: 21444869

Group type: EXPERIMENTAL
Intervention: 24-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Number of subjects: 356

Group type: COMPARATOR
Intervention: 4-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Number of subjects: 356
Study: 19490278

Group type: EXPERIMENTAL
Intervention: Youth in foster care
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Younger adolescents and those in relative placement
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Youth in group homes, those who experienced parental death, or had a history of physical/emotional abuse or attempted suicide
Number of subjects: 56
Study: 16865997

Group type: EXPERIMENTAL
Intervention: Waterpik Sensonic
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sonicare Elite
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral‐B Sonic Complete
Number of subjects: 144

Group type: COMPARATOR
Intervention: Oral‐B Indicator (manual)
Number of subjects: 144
Study: 12953289

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (IgG) enzyme‐linked immunosorbent assay (ELISA) for measuring serum antibody concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control methodology in ELISA
Number of subjects: 0
Study: 11062357

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN; 10 mg/day) for 2 years
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN; 10 mg/day) for 3 years
Number of subjects: 53
Study: 9425591

Group type: EXPERIMENTAL
Intervention: Immunotherapy with a mixture of multiple allergen extracts
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Injection therapy using synthetic fragments of the major allergen responsible for allergic reactions to cats
Number of subjects: 121
Study: 8375429

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bromocriptine-levodopa combination therapy
Number of subjects: 96
Study: 3758170

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4, 1.2, 3.6, 10.8, 32.4, 97.2 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (Dextrose 5% in water)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 2
Study: 30721950

Group type: EXPERIMENTAL
Intervention: Oral micronized P4 (3 × 200 mg/d IM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E2 (5 mg IM) and oral placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: E2 IM and oral micronized P4
Number of subjects: 40
Study: 28397581

Group type: EXPERIMENTAL
Intervention: Denosumab plus native vitamin D
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Denosumab plus ELD
Number of subjects: 56
Study: 26456492

Group type: EXPERIMENTAL
Intervention: Gum-elastic bougie (GEB) during chest compressions
Number of subjects: 17

Group type: COMPARATOR
Intervention: No gum-elastic bougie (without GEB) during chest compressions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GEB during chest compressions
Number of subjects: 17

Group type: COMPARATOR
Intervention: No GEB during chest compressions
Number of subjects: 17
Study: 24903517

Group type: EXPERIMENTAL
Intervention: Regret model
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dual-processing model
Number of subjects: 41
Study: 22016074

Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Shock-only
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Shock following ATP
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Inappropriate ATP
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Shock therapy
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Episodes between 200 and 250 bpm
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Episodes >250 bpm
Number of subjects: 1530
Study: 21177179

Group type: EXPERIMENTAL
Intervention: Ozone therapy plus sulfasalazine delivered via a colon therapy system
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sulfasalazine delivered via retention enema (Control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sulfasalazine delivered via colon therapy system
Number of subjects: 54
Study: 18025627

Group type: EXPERIMENTAL
Intervention: Manual SICS superior incision
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Manual SICS temporal incision
Number of subjects: 64

Group type: COMPARATOR
Intervention: Phacoemulsification clear corneal incision
Number of subjects: 64

Group type: COMPARATOR
Intervention: Phacoemulsification scleral pocket incision
Number of subjects: 64
Study: 16108781

Group type: EXPERIMENTAL
Intervention: Nursing-led inpatient unit
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 175
Study: 11822750

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 337

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg
Number of subjects: 337
Study: 9725371

Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve blockade (T3 through T6) with bupivacaine through an indwelling catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of local anesthetics (bupivacaine) and opioid analgesics (fentanyl) through a thoracic epidural catheter
Number of subjects: 30
Study: 8151479

Group type: EXPERIMENTAL
Intervention: High-fat formula
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-carbohydrate formula
Number of subjects: 10
Study: 3166629

Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption with a meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption after a high-energy meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diluted ethanol consumption with different meal compositions
Number of subjects: 18
Study: 28895175

Group type: EXPERIMENTAL
Intervention: Case management intervention (nurses and physiotherapists) providing general case management, general information, specific information, and continuity and safety over 12 months with one or more home visits per month.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 153
Study: 27072372

Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation (FATmax) intensity, 5 days/week, 1 hour/day for 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 24508649

Group type: EXPERIMENTAL
Intervention: Synchronous co-activation for 3 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asynchronous co-activation for 3 hours
Number of subjects: 0
Study: 22895063

Group type: EXPERIMENTAL
Intervention: Tight control (<125/<80 mm Hg)
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Usual control (125-134/80-84 mm Hg)
Number of subjects: 3518

Group type: EXPERIMENTAL
Intervention: Combined analysis of all patients
Number of subjects: 3518
Study: 20441414

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with amniotic membrane implantation and mitomycin C (MMC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC) only
Number of subjects: 30
Study: 17921398

Group type: EXPERIMENTAL
Intervention: Normal serum zinc concentrations
Number of subjects: 578
Study: 16509426

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy by fluvoxamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controlled therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stroop test
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: WMS‐R
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Y‐BOCS mean score
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MOCI score
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HDRS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: STAI scores
Number of subjects: 32
Study: 12505235

Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory BP monitoring in a subgroup of the HOPE study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office BP measurements
Number of subjects: 0
Study: 10767520

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus L-thyroxine (75 mcg/day for 3 months)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg/day for 5 days/month for 3 months)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus L-thyroxine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 16
Study: 8866594

Group type: EXPERIMENTAL
Intervention: 6 microg formoterol b.i.d.
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 12 microg formoterol b.i.d.
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 24 microg formoterol b.i.d.
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 1386856

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Sociotropy-Autonomy distinction
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Endogeneity and autonomy
Number of subjects: 217
Study: 6437815

Group type: EXPERIMENTAL
Intervention: TTS‐NTG (25 mg per 10 cm2)
Number of subjects: 10
Study: 31656173

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (ET) 3 times per week for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: No attention control group (CG)
Number of subjects: 60
Study: 28704213

Group type: EXPERIMENTAL
Intervention: Menstrual pad HPV testing
Number of subjects: 529
Study: 25952589

Group type: EXPERIMENTAL
Intervention: TASK II intervention (n=123)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Information, Support, and Referral (n=131)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: TASK II intervention
Number of subjects: 254

Group type: COMPARATOR
Intervention: Information, Support, and Referral
Number of subjects: 254
Study: 25322847

Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sphygmocor
Number of subjects: 73
Study: 22560323

Group type: EXPERIMENTAL
Intervention: Coapsys device implantation
Number of subjects: 1
Study: 19067606

Group type: EXPERIMENTAL
Intervention: 3rd dose of 1.25 microg H5N1 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3rd dose of 2.5 microg H5N1 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3rd dose of 5 microg H5N1 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3rd dose of 10 microg H5N1 vaccine
Number of subjects: 0
Study: 17544875

Group type: EXPERIMENTAL
Intervention: Single-dose inactive trivalent influenza vaccine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Infliximab and immunomodulatory therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 80
Study: 15718325

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (six weekly sessions of 2 hours)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 262
Study: 11545630

Group type: COMPARATOR
Intervention: Normal BMI (22.0-24.9)
Number of subjects: 21121

Group type: EXPERIMENTAL
Intervention: Lean BMI (< 22.0)
Number of subjects: 21121

Group type: EXPERIMENTAL
Intervention: Overweight BMI (25.0-29.9)
Number of subjects: 21121

Group type: EXPERIMENTAL
Intervention: Obese BMI (>= 30.0)
Number of subjects: 21121

Group type: EXPERIMENTAL
Intervention: BMI and neovascular ARM
Number of subjects: 21121
Study: 9286000

Group type: EXPERIMENTAL
Intervention: Perceived alcohol availability
Number of subjects: 3372

Group type: EXPERIMENTAL
Intervention: Drinking in a public location
Number of subjects: 3372
Study: 8335174

Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 3524182

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.0 million units) followed by 72 hours of heparin infusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo followed by heparin infusion
Number of subjects: 38
Study: 2493413

Group type: EXPERIMENTAL
Intervention: 1.5 mg/h NTG infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.5 mg/h NTG infusion after 12-hour infusion-free interval
Number of subjects: 10
Study: 31855057

Group type: EXPERIMENTAL
Intervention: JOIN for ME
Number of subjects: 66

Group type: COMPARATOR
Intervention: JOIN for ME enhanced program
Number of subjects: 66
Study: 30858273

Group type: EXPERIMENTAL
Intervention: Microteaching combined with the BOPPPS method
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 105
Study: 28619229

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sputum smear microscopy (standard of care)
Number of subjects: 0
Study: 25037243

Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (IVD) - 500 μg/0.1 ml
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) - 1.25 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intravitreal diclofenac (IVD)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study: 23980355

Group type: EXPERIMENTAL
Intervention: Routine therapy + Xuebijing (XBJ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 32
Study: 21459690

Group type: EXPERIMENTAL
Intervention: Strength training (4 sessions per week at 50% to 80% of repetition maximum for 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 16
Study: 17987348

Group type: EXPERIMENTAL
Intervention: Physicians' responses to patients' requests for antidepressants
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Physicians' cognitive reactions to patient requests
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Physicians' prescribing behavior influenced by patient requests
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Influence of time and attitudes on prescribing
Number of subjects: 22
Study: 18942528

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15798812

Group type: EXPERIMENTAL
Intervention: Anti-retroviral therapy plus N-acetyl-L-cysteine (NAC) supplementation (600 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Anti-retroviral therapy plus placebo
Number of subjects: 30
Study: 11789125

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (donepezil, rivastigmine, metrifonate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginkgo extract EGb 761R
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9815743

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) at 150 IU/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) at 300 IU/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 43
Study: 7687510

Group type: EXPERIMENTAL
Intervention: Terfenadine (Selddane)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10